A blockade of the VEGF signaling pathway with anti-angiogenic agents can have an enhanced anti-tumor immune effect because prior research has demonstrated that the Vascular Endothelial Growth Factors (VEGF)/VEGFR signaling pathway inhibits anti-tumor immune responses not only by producing a hypoxic microenvironment but also through other complex mechanisms to produce immunosuppressive effects (42–45). The gene discussed is KDR; the disease is neoplasm.